Skip to main content

Table 2 Summary and comparison of [68Ga]Ga-DOTA-TOC PET/CT results

From: Tumour-to-liver ratio determined by [68Ga]Ga-DOTA-TOC PET/CT as a prognostic factor of lanreotide efficacy for patients with well-differentiated gastroenteropancreatic-neuroendocrine tumours

Variable

Whole patients (n = 31)

No previous treatment (n = 15)

Previous treatment (n = 16)

p value

Krenning score (2/3/4)

3/6/22

1/4/10

2/2/12

0.562

Median tumour-to-liver ratio (TLR)

8.1 (1.0–36.9)

6.5 (1.7–36.9)

10.9 (1.0–36.1)

0.299

Median maximum standardized uptake value (SUVmax)

42.9 (5.9–180.1)

50.7 (6.8–180.1)

63.0 (5.9–143.1)

0.446

Median whole tumour volume (WTV, cm3)

58.9 (0.0–617.7)

71.2 (0.0–617.7)

26.1 (0.0–219.5)

0.216

Median total receptor expression (TRE)

778.5 (0.0–9694.0)

1186.1 (0.0–9694.0)

687.2 (0.0–5007.3)

0.188

Mean liver mean SUV (SUVmean)

5.5 ± 1.7 (2.8–9.3)

5.4 ± 1.7 (2.8–9.3)

5.6 ± 1.7 (2.8–8.6)

0.626

  1. PET positron emission tomography, CT computed tomography